IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the patent of:

Alexander MacGregor

Patent Number: 7,381,424 B2 Atty. Docket No. 026806-00017

Issued: June 3, 2008

For: HYDROSTATIC DELIVERY SYSTEM FOR CONTROLLED

DELIVERY OF AGENT

REQUEST FOR CERTIFICATE OF CORRECTION

Mail Stop - Certificates of Corrections Commissioner for Patents P.O. Box 1450 Alexandria. Virginia 22313-1450

October 26, 2009

Sir:

The undersigned respectfully requests that a Certificate of Correction be issued for the above-identified patent as indicated on the attached PTO-1050 Forms.

REMARKS

This request is being made in order to correct several errors noted throughout the Letters Patent. It is respectfully submitted that no new matter has been added.

The required fee of One Hundred Dollars (\$100.00) for a Certificate of Correction is being submitted concurrently herewith. In the event that any additional fees are due with respect to this paper, please charge our Deposit Account No. 01-2300, referencing Atty. Docket No. 026806-00017.

Respectfully submitted,

am C. Pussell

Dawn C. Russell Attorney for Applicant Reg. No. 44,751

Customer No.: 04372 1050 Connecticut Avenue, N.W. Suite 400 Washington, D. C. 20036-5339 Tel (202) 857-6000 Fax (202) 857-6395

DCR:mmg

Enclosures: Form PTO-1050 (6)

PATENT NO.: US 7.381.424 B2

DATED:

June 3, 2008

Page 1 of 6

INVENTOR(S): Alexander MACGREGOR

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below.

IN THE LETTERS PATENT:

Please amend as follows:

Column 3, line 22, delete "therefore," and insert -- Therefore, --.

Column 8, line 1, delete "alpha." and insert -- α --;

Column 8, line 5, delete "17. alpha." and insert -- 17α --;

Column 8, line 6, delete "10. alpha." and insert -- 10α --;

Column 8, line 19, delete "beta." and insert -- \(\beta \) --;

Column 8, line 28, delete "B.sub, 12" and insert -- B₁₂--:

Column 8, line 38, delete "alpha." and insert -- α --;

Column 8, line 45, delete "carboxylicacid" and insert -- carboxylic acid --;

Column 8, line 55, delete "carboxylicacid" and insert -- carboxylic acid --; and

Column 8, line 61, delete "1,4" and insert -- 1,4 --.

MAILING ADDRESS OF SENDER:

Customer No. 04372 ARENT FOX LLP 10 50 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339 Patent No. US 7,381,424 B2

No. of add'l copies @ 30¢ per page

PATENT NO.: US 7.381.424 B2

DATED:

June 3, 2008

Page 2 of 6

INVENTOR(S): Alexander MACGREGOR

Treation (o).

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE LETTERS PATENT:

Please amend as follows:

Column 12, line 25, delete "Prefreably," and insert -- Preferably, --.

Column 16, line 33, delete "intrest" and insert -- interest --; and

Column 16, line 35, delete "interst" and insert -- interest --.

Column 18, delete lines 13 - 56 in their entirety; and

Column 18, line 66, delete "interestin" and insert -- interest in --.

Column 19, line 26, delete "Synamic" and insert -- Dynamic --;

Column 19, line 44, delete "orderto", and insert -- order to --:

Column 19, line 46, delete "swolien" and insert -- swollen --:

Column 19, line 52, delete "Materals" and insert -- Materials --:

Column 19, line 55, delete "Appaatus" and insert -- Apparatus --;

MAILING ADDRESS OF SENDER:

Patent No. US 7,381,424 B2

No. of add'l, copies @ 30¢ per page

Customer No. 04372 ARENT FOX LLP 10 50 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339

PATENT NO :

US 7.381.424 B2

DATED

June 3, 2008

Page 3 of 6

INVENTOR(S): Alexander MACGREGOR

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE LETTERS PATENT:

Please amend as follows:

Column 19, line 61, delete "Merler-Taledo" and insert -- Mettler-Toledo --: and delete "forliquids" and insert -- for liquids --: and

Column 19, line 67, delete "hydrodynaic" and insert -- hydrodynamic --,

Column 20, line 8, delete "This" and insert -- this --:

Column 20, line 9, delete "inerest" and insert -- interest --:

Column 20, line 17, after "over" insert the following: -- time wherein the influx of fluid is equal to the efflux of caffeine. This represents a controlled increase in the dynamic profile of a tablet, which reaches and maintains a maximum volume after a period of time (depending upon the ratio of the hydrodynamic fluid-imbibing polymer, to hydrostatic pressure modulating agent). Figure 4 shows the corresponding drug release (dissolution profile) for a formulation comprising a hydrostatic couple of the present invention, and displays a linear, zero-order release of an agent of interest for over 16 hours. Figures 2 and 4 demonstrate how the volume increase in a --

MAILING ADDRESS OF SENDER:

Customer No. 04372 ARENT FOX LLP 10 50 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339

Patent No. US 7,381,424 B2 No of add't copies

@ 30¢ per page

PATENT NO.: US 7.381.424 B2

DATED: June 3, 2008 Page 4 of 6

INVENTOR(S): Alexander MACGREGOR

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE LETTERS PATENT:

Please amend as follows:

CONTINUED - Column 20, after line 17, insert the following paragraphs and table:

-- delivery system comprising a hydrostatic couple is reduced, resulting in an increased and continuous efflux rate. Because the rate of efflux of the agent of interest is independent on the concentration of the agent but dependent on the hydrostatic pressure within the delivery system, the kinetics of agent release is zero-order.

Examples 3-6:

In these examples hydrostatic delivery systems for extended release formulation of various therapeutic agents are presented. Two formulations (Formula 1 and Formula 2) are used to illustrate how the hydrostatic couple as described herein can be used to achieve zero-order kinetics and predictably different release rates. Formula 1 exhibits faster rates of drug release than that observed with Formula 2. The rate of release of the agent of interest may be selected considering several variables, for example, but not limited to the solubility of the agent of --

MAILING ADDRESS OF SENDER:

Patent No. US 7,381,424 B2

No. of add'l. copies @ 30¢ per page

Customer No. 04372 ARENT FOX LLP 10 50 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339

PATENT NO: US 7 381 424 B2

DATED: June 3, 2008 Page 5 of 6

INVENTOR(S): Alexander MACGREGOR

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE LETTERS PATENT:

Please amend as follows:

CONTINUED - Column 20, after line 17, insert the following paragraphs and table:

-- interest, and pharmacological activity of the agent of interest. For example, with decreased solubility of an agent of interest, faster release of the agent may be desired such as that provided by, but not limited to, Formula 1. In the case of a soluble agent of interest, slower release of the agent from the delivery system may be desired, for example, but not limited to, using a hydrostatic couple as provided in Formula 2. It is to be understood, however, that the formulation of the hydrostatic couple may be varied as required to obtain a desired rate of release of an agent of interest. --

MAILING ADDRESS OF SENDER-

Customer No. 04372 ARENT FOX LLP 10 50 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339 Patent No. US 7,381,424 B2

No. of add'l copies @ 30¢ per page

PATENT NO.: US 7,381,424 B2

DATED: June 3, 2008 Page 6 of 6

INVENTOR(S): Alexander MACGREGOR

It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

IN THE LETTERS PATENT:

Please amend as follows:

CONTINUED - Column 20, after line 17, insert the following paragraphs and table:

-- Example 3 Extended Release Theophylline 80 mg

Table 2

Extended Release Theophylline

Components	Formula-1	Formula-2
Theophylline USP	80.00 mg	80.00 mg
Carbopol 971P NF	320.00 mg	320.00 mg
Crospovidone XL-10	6.40 mg	0.00 mg
Crospovidone INF-10	0.00 mg	6.40 mg
Sodium Lauryl Sulphate NF	4.00 mg	4.00 mg
Colloidal Silicon Dioxide NF	3.00 mg	3.00 mg

Column 21, line 23, delete "37+C" and insert -- 37° C --.

MAILING ADDRESS OF SENDER:

Customer No. 04372 ARENT FOX LLP 10 50 Connecticut Avenue, N.W., Suite 400 Washington, D.C. 20036-5339 Patent No. US 7.381.424 B2

No. of add'l. copies @ 30¢ per page